|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Melanoma | |||||
| Sarcoma | |||||
| 2 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Connective and Soft Tissue | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neuroectodermal Tumors | |||||
| Neuroendocrine Tumors | |||||
| Nevi and Melanomas | |||||
| 3 | Additional drug interventions recognized in this trial | ||||
| Melphalan | |||||
| 4 | More general drug interventions related to this trial | ||||
| Alkylating Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Alkylating | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Myeloablative Agonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| National Cancer Institute (NCI) | |||||